Objective Obstructive sleep apnea (OSA) has been associated with increased risk for cardiovascular events, possibly mediated by endothelial dysfunction. The current study evaluates the association between invasive coronary endothelial dysfunction and OSA in patients with nonobstructive coronary atherosclerosis.
Methods All patients who had undergone both polysomnography and an invasive coronary vasomotor study at the Mayo Clinic, Rochester, Minnesota, from January 1997 to August 2011 were identified (n = 143). OSA was defined as an apnea-hypopnea index of 5 or higher. Three endpoints of coronary endothelial functionpercentage change in coronary artery diameter at the mid and distal left anterior descending artery to intracoronary acetylcholine and percentage change in coronary blood flow to intracoronary acetylcholine -were assessed. Differences between patients with OSA (n = 102) and those without OSA (n = 41) were evaluated using multivariate analysis of variance. Follow-up mortality data were collected and Kaplan-Meier curves were plotted to evaluate differences in mortality between patients with and without OSA.
Results Patients with OSA were more likely to have hypertension compared with patients without OSA. OSA was not significantly associated with coronary endothelial dysfunction on univariate analysis (P = 0.23) and after adjustment for hypertension (P = 0.19). Similarly, there was no significant difference in coronary endothelial function in patients who had oxygen desaturation of less than 90% during polysomnography (P = 0.42). There was a trend toward higher mortality in patients with OSA compared with those without OSA, but this did not reach statistical significance (5 vs . 0% at 10 years, P = 0.25).
Conclusion
The current study suggests that OSA is not an independent risk factor for coronary endothelial dysfunction in patients with early coronary atherosclerosis. Adverse coronary outcomes in patients with OSA may be independent of coronary endothelial dysfunction. 
Introduction
Sleep disordered breathing affects B24% of men and 9% of women between the ages of 30 and 60 years [1] , and obstructive sleep apnea (OSA) has been associated with a 70% relative increased risk of cardiovascular morbidity and mortality [2, 3] . Endothelial dysfunction is associated with the pathogenesis and clinical course of atherosclerosis [4, 5] and a four-fold increased risk for cardiovascular events [6] [7] [8] . Several studies have shown that OSA is associated with endothelial dysfunction in peripheral vessels [9] [10] [11] . Other studies associated OSA with endothelial dysfunction by demonstrating increased levels of inflammatory markers [12] [13] [14] and reduced levels of nitric oxide [15] . It has been hypothesized that the increased risk for cardiovascular events in patients with OSA might be mediated by endothelial vasomotor dysfunction [16] . To address this hypothesis we examined the association of OSA with invasively determined coronary endothelial dysfunction.
Methods

Study design, study population, and data collection
After approval by the Mayo Clinic Institutional Review Board, all patients who had undergone polysomnography at the Mayo Clinic, Rochester, Minnesota, from January 1997 to August 2011 were identified. This database of 51 360 patients was cross-referenced with the coronary physiology and imaging database at the Mayo Clinic to identify those patients who had also undergone an invasive coronary vasomotor study (n = 143). Four patients had undergone more than one invasive coronary vasomotor evaluation test, and only the earliest test was included in the analysis. Eleven patients had undergone polysomnography twice -only the polysomnogram in closest temporal relation with the coronary vasomotor assessment test was included in the study. The median time between the two tests was 20.3 months (interquartile range 0.03-59.1). Forty-three patients had undergone the two tests within 6 months of each other.
The medical records were reviewed by one investigator and the patient characteristics, risk factors, laboratory values, medications, polysomnography data, and coronary vasomotor study details were recorded. We divided the patients into two groups according to the presence (n = 102) or absence (n = 41) of OSA. OSA was defined as an apnea-hypopnea index of 5 or higher on polysomnography [17] . Forty-six of the 102 patients with OSA had moderate to severe OSA (apnea-hypopnea index Z 15). We tested for a difference in coronary endothelial function endpoints between patients with OSA and those without OSA ( Fig. 1 ).
Coronary vasomotor studies were conducted for clinical indications, typically chest pain syndrome with no or mild epicardial coronary artery disease. Exclusion criteria for carrying out invasive coronary vasomotor assessments at our institution include a history of ischemic heart disease (myocardial infarction, percutaneous coronary revascularization, coronary artery bypass grafting, unstable angina), angiographic coronary artery lesions of greater than 40% luminal diameter stenosis, heart failure with an ejection fraction less than 40%, valvular heart disease, stroke, or significant hepatic, renal, or inflammatory disease within 6 months of the invasive study. Pregnant or lactating patients were excluded. Patients who required treatment with positive inotropic agents other than digoxin during the study were excluded. Long-acting nitrates or calciumchannel blockers were withheld for 36-48 h before the study to allow assessment of baseline coronary physiology.
Diagnostic coronary angiography and invasive endothelial function assessment was performed as previously described [8, 18] . In brief, a Doppler guide-wire (FloWire; Volcano Corp., Rancho Cordova, California, USA) within a coronary infusion catheter was positioned in the midportion of the left anterior descending coronary artery. Average peak velocity (APV) was obtained from Doppler flow velocity spectra [19] . Coronary artery diameter (DIA) measurements were made in the mid left anterior descending artery segment 5 mm distal to the tip of the Doppler and in the distal left anterior descending artery using an online quantitative coronary angiography program (Medis Corporation, Leiden, The Netherlands) [20] . Analysis of data from our laboratory shows that the intraobserver variability is 6±5 and 2.0±2.4% for the DIA and APV, respectively [8, 21] . Assessment of coronary endothelial function was performed by selective infusion of increasing concentrations of acetylcholine (10 -6 , 10 -5 , and 10 -4 mol/l) at 1 ml/min at 3 min intervals with Doppler measurements and coronary angiography after each infusion. The relative changes in DIA at the mid and distal left anterior descending artery and in APV to intracoronary acetylcholine were calculated. Coronary blood flow (CBF) was determined from the equation:
We also collected follow-up mortality data from the Mayo registration records (n = 141) to determine whether there was a difference in mortality between patients with and those without OSA. Further, a questionnaire was sent to patients to determine major adverse cardiac and cerebrovascular events (MACCE) including death, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, or stroke (n = 50).
Statistical analysis
We carried out a power analysis for a pooled two-sample t-test using the above sample size. Using a type 1 error of 0.0167 (to keep an overall error rate of 0.05 for three endpoints) and pooled SD of 25 for percent change in DIA (from our data), we had 99% power to detect a 20% difference in DIA at both the mid and distal left anterior descending artery between patients with and those without OSA. 
Results
The baseline patient characteristics of those with and those without OSA are shown in Table 1 . Patients with OSA were significantly more likely to have hypertension; otherwise, the two groups were similar in terms of age, sex, smoking history, diabetes mellitus, hyperlipidemia, and use of aspirin, lipid-lowering drugs, and antihypertensive agents. Testing for coronary endothelial function revealed that the relative change in DIA (at both the mid and distal left anterior descending artery segments) and CBF in response to acetylcholine in patients with OSA was not significantly worse compared with that in patients without OSA (Table 1) . OSA was not significantly associated with coronary endothelial dysfunction on univariate analysis (P = 0.23; Fig. 2 ) or after adjustment for hypertension (P = 0.19). Similarly, coronary endothelial function was not worse in patients who had oxygen desaturation of less than 90% for at least 10% of sleep time during polysomnography (P = 0.42). A test for interaction yielded no evidence (P = 0.26) of the association between OSA and coronary endothelial function being different between men and women. In addition, there was no significant correlation between moderate-severe OSA [defined as an apnea-hypopnea index of 15 or higher (n = 46)] and coronary endothelial dysfunction (P = 0.10). Coronary endothelial response was not different between the 12 patients who were on treatment for OSA [and were compliant with their continuous positive airway pressure (CPAP) for at least 6 weeks] before the cardiac catheterization and the remainder of the OSA group (P = 0.90). Even if these treated patients are excluded from the OSA group, there is still no difference in association between OSA and coronary endothelial function [multivariate analysis of variance P = 0.35 (unadjusted) and P = 0.32 (adjusted)]. If only the patients who had undergone polysomnography within 6 months of their coronary endothelial function test were considered (n = 43, OSA n = 30, without OSA n = 13), OSA was not significantly associated with coronary endothelial dysfunction on univariate analysis (P = 0.12) or after adjustment for hypertension (P = 0.15). Testing for coronary endothelium-independent function with coronary flow reserve to adenosine revealed that patients with OSA did not have a statistically significantly worse coronary flow reserve in response to adenosine when compared with patients without OSA (P = 0.93; Table 1 ).
Follow-up data on mortality and MACCE from the time of polysomnography are shown in Figs 3 and 4. All patients without OSA were alive after 10 years of follow-up. Even though there was a trend toward worse survival in patients with OSA, there was no statistically significant difference in mortality between patients with OSA and those without OSA. Similarly, there was no statistically significant difference in MACCE between patients with OSA and those without OSA.
Discussion
To our knowledge, the current study is the first to use invasively determined parameters for coronary endothelial dysfunction in humans to assess independent risk for OSA for endothelial dysfunction. The study suggests that in patients with early coronary atherosclerosis, OSA is not an independent risk factor for coronary endothelial dysfunction and that both of these risk factors may contribute independently to cardiovascular events in humans.
Previous studies have suggested OSA may be associated with endothelial dysfunction in patients with early coronary atherosclerosis and that OSA may induce endothelial dysfunction, resulting in an increased propensity for cardiovascular events [16] . However, our study found no correlation between OSA or hypoxemia and coronary endothelial dysfunction. The pathogenesis of increased cardiovascular risk in patients with OSA remains incompletely understood but is likely to be multifactorial. A diverse range of mechanisms including sympathetic nervous system overactivity, selective activation of inflammatory molecular pathways, abnormal coagulation, and metabolic dysregulation (particularly involving insulin resistance and disordered lipid metabolism) [22] may be more important than coronary endothelial dysfunction in increasing the risk for coronary artery disease in patients with OSA. These systemic changes in patients with OSA may be more prominent in the peripheral vasculature [23] [24] [25] than in the coronary vascular tree. Increased sympathetic activity in OSA leads to systemic hypertension [23] , which is a well-known risk factor for endothelial dysfunction and coronary artery disease. Indeed, the association of OSA with flowmediated brachial blood flow in response to cuff occlusion [26] or sodium nitroprusside administration [24] is stronger in patients with OSA and combined hypertension. In the present study, patients with OSA had increased prevalence of hypertension and there was a trend toward higher likelihood to be treated with b-blockers compared with patients without OSA. The use of b-blockers in the patients with OSA might have attenuated the increased sympathetic response and thus possibly the pathogenesis for worse coronary endothelial dysfunction [27] .
OSA may increase myocardial events because of acute hemodynamic local effects on coronary plaques at night rather than chronic inflammatory effects on endothelial function. Nocturnal hypoxemia results in sympathetic activation and surges in blood pressure, which may lead to plaque rupture, coronary thrombosis, and myocardial infarction [28, 29] . It is possible that the increased sympathetic activity in OSA may result in increased cardiovascular events by increasing heart failure [30] and arrhythmias [31] [32] [33] rather than coronary endothelial dysfunction and coronary artery disease. A recent paper casts further doubt on OSA being an additional independent risk factor for the incidence of coronary artery disease [30] .
It is possible that there is no direct cause and effect between OSA and coronary endothelial dysfunction but that they often coexist in patients with multiple risk factors. Multiple confounding factors may be responsible for endothelial dysfunction in patients with OSA. Such confounding factors include obesity [34, 35] , chronic obstructive pulmonary disease [36, 37] , and hypertension [23] , which have been associated with increased inflammatory markers, cardiovascular events, and endothelial dysfunction. In the Sleep Heart Health study [26] , which is the only large study to date, OSA was associated with peripheral endothelial dysfunction (measured by brachial artery flow-mediated dilatation) on univariate analysis but was not an independent predictor of endothelial dysfunction after adjustment for obesity (except in patients with hypertension after subgroup analysis).
Circulating endothelial cells and endothelial progenitor cells are novel surrogate markers of endothelial damage and repair, respectively. A most recent study [38] showed that coexistent mild-to-moderate sleep disordered breathing in patients with acute myocardial infarction increased the mobilization, proliferative, and angiogenic capacities of endothelial progenitor cells, angiogenic T-cell numbers, and vascular endothelial growth factor expression in monocytes compared with patients without sleep disordered breathing. Further, induced hypoxemia in vitro had similar effects on healthy endothelial progenitor cell functions. This confirmed earlier findings [39, 40] , which showed no difference in circulating endothelial cells or endothelial progenitor cells in patients with sleep apnea versus patients with hypertension or healthy controls. Further, there was no difference in circulating endothelial cells or endothelial progenitor cells after CPAP treatment. This further supports the possibility that OSA is not an independent cause of endothelial dysfunction.
Limitations of our study include its retrospective nature with possible selection bias as the patients included were referred for coronary angiography with vasomotor testing because of symptoms. This may be the reason for inclusion of a control group with coronary endothelial dysfunction due to a relatively high prevalence of traditional risk factors (smoking, hypertension, hyperlipidemia, and diabetes) known to be associated with endothelial dysfunction. This may have made independent further worsening in coronary endothelial function because of OSA less likely. Conversely, the advantage of having a control group with significant risk factors is that most patients in the general population with OSA (as in our study patients with OSA) also have a high prevalence of these risk factors [23, 30] and our aim was to study whether OSA is an independent further risk for coronary endothelial dysfunction in patients with early atherosclerosis. However, it may not be possible to extrapolate the data from this study cohort to patients with OSA without other significant risk factors for coronary artery disease. Our study has several strengths: (i) the assessment of endothelial dysfunction in patients with OSA was performed for the first time in the coronary vasculature rather than relying on peripheral surrogates such as brachial ultrasound or systemic inflammatory markers, and (ii) previous studies showing an association of OSA with endothelial dysfunction were small (< 50 patients) [9] [10] [11] 40 ] making our study much larger and less prone to a type II error due to chance. A large randomized prospective trial to test the hypothesis that OSA is associated with coronary endothelial dysfunction would be ideal. This would involve enrolling asymptomatic patients to undergo both polysomnography and an invasive coronary endothelial function test and then comparing endothelial function in patients with and those without OSA. Further, it would be of interest to treat patients with OSA with CPAP and then to reperform a coronary endothelial function test to see whether there is an improvement in endothelial function with treatment.
Conclusion
The current study suggests that OSA is not independently associated with coronary endothelial dysfunction in patients with early coronary atherosclerosis. Thus, adverse coronary outcomes in patients with OSA may be indirect and independent of coronary endothelial dysfunction, and assessment for both conditions may be additive to risk stratification among patients with early coronary atherosclerosis.
